Our NASH Treatment Focus
Resmetirom is designed to target the underlying causes of NASH in the liver.
Resmetirom is designed to target the underlying cause of NASH in the liver.
A growing body of evidence demonstrates the need for therapies that treat the underlying pathophysiology of NASH with liver fibrosis to halt or reverse disease progression.
Madrigal has discovered an innovative investigational therapy that has the potential to address this need. Our most advanced clinical candidate, resmetirom, is a once daily, oral thyroid hormone receptor (THR) β-selective agonist that is currently being studied in Phase 3 trials.
Resmetirom is designed to target the underlying causes of NASH by reducing or eliminating liver fat (steatosis) as well as reducing liver inflammation, liver cell ballooning (hepatocyte cell death), and liver fibrosis that can lead to cirrhosis.
Phase 3 and Phase 2 clinical data support the potential for resmetirom to become the first-to-market therapy for NASH patients with liver fibrosis.
Research conducted to date shows resmetirom to be generally safe, well-tolerated and efficacious in treating the underlying causes of NASH while lowering LDL cholesterol and other atherogenic lipids and lipoproteins.